PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7208580-1	1980	Part 6: Liberation of glaucine from Tussiglauzin Dragees (author"s transl)].	glaucine	22-30	tankyrase 2	Homo sapiens	0-6
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	glaucine	66-74	monoamine oxidase A	Homo sapiens	157-162
30216681-4	2019	Both (R)- and (S)-glaucine also antagonized alpha1 receptors, but they behaved very differently to the other compounds at 5-HT2 receptors: (S)-glaucine acted as a partial agonist at all three 5-HT2 receptor subtypes, whereas (R)-glaucine appeared to act as a positive allosteric modulator at the 5-HT2A receptor.	glaucine	139-151	5-hydroxytryptamine receptor 2A	Homo sapiens	122-136
25670016-0	2015	Glaucine inhibits breast cancer cell migration and invasion by inhibiting MMP-9 gene expression through the suppression of NF-kappaB activation.	glaucine	0-8	matrix metallopeptidase 9	Homo sapiens	74-79
25670016-0	2015	Glaucine inhibits breast cancer cell migration and invasion by inhibiting MMP-9 gene expression through the suppression of NF-kappaB activation.	glaucine	0-8	nuclear factor kappa B subunit 1	Homo sapiens	123-132
25670016-3	2015	We further show that glaucine significantly blocks phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression and activity in a dose-dependent manner.	glaucine	21-29	matrix metallopeptidase 9	Homo sapiens	97-102
25670016-4	2015	Results from reporter gene and electrophoretic mobility shift assays revealed that glaucine inhibits MMP-9 expression by suppressing activation of the nuclear transcription factor nuclear factor-kappaB (NF-kappaB).	glaucine	83-91	matrix metallopeptidase 9	Homo sapiens	101-106
25670016-4	2015	Results from reporter gene and electrophoretic mobility shift assays revealed that glaucine inhibits MMP-9 expression by suppressing activation of the nuclear transcription factor nuclear factor-kappaB (NF-kappaB).	glaucine	83-91	nuclear factor kappa B subunit 1	Homo sapiens	203-212
25670016-5	2015	Moreover, glaucine attenuates PMA-induced IkappaBalpha degradation and nuclear translocation of NF-kappaB.	glaucine	10-18	NFKB inhibitor alpha	Homo sapiens	42-54
25670016-5	2015	Moreover, glaucine attenuates PMA-induced IkappaBalpha degradation and nuclear translocation of NF-kappaB.	glaucine	10-18	nuclear factor kappa B subunit 1	Homo sapiens	96-105
25670016-6	2015	Finally, we also found that glaucine inhibits invasion and MMP-9 expression in the highly metastatic MDA-MB-231 breast cancer cell line.	glaucine	28-36	matrix metallopeptidase 9	Homo sapiens	59-64
25670016-7	2015	Taken together, our findings indicate that the MMP-9 inhibitory activity of glaucine and its abilities to attenuate IkappaBalpha and NF-kappaB activities may be therapeutically useful as a novel means of controlling breast cancer growth and invasiveness.	glaucine	76-84	matrix metallopeptidase 9	Homo sapiens	47-52
25670016-7	2015	Taken together, our findings indicate that the MMP-9 inhibitory activity of glaucine and its abilities to attenuate IkappaBalpha and NF-kappaB activities may be therapeutically useful as a novel means of controlling breast cancer growth and invasiveness.	glaucine	76-84	NFKB inhibitor alpha	Homo sapiens	116-128
25670016-7	2015	Taken together, our findings indicate that the MMP-9 inhibitory activity of glaucine and its abilities to attenuate IkappaBalpha and NF-kappaB activities may be therapeutically useful as a novel means of controlling breast cancer growth and invasiveness.	glaucine	76-84	nuclear factor kappa B subunit 1	Homo sapiens	133-142
23988488-0	2013	Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse.	glaucine	91-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
19481591-5	2009	Glaucine succeeded to enhance LPS and zymosan-induced IL-10 production.	glaucine	0-8	interleukin 10	Mus musculus	54-59
17243616-1	2006	The author describes a clinical symptom complex which appears in some patients as a central nervous system side-effect of conventional doses of glaucine, a non-narcotic antitussive preparation, used in outpatients; the symptom complex is described by the author as acute glaucine syndrome (AGS).	glaucine	144-152	jagged canonical Notch ligand 1	Homo sapiens	290-293
17243616-2	2006	Clinical manifestations of AGS are the following: 1) very prominent fatigue, which occurs acutely after taking a conventional dose of glaucine and making any kind of professional activity impossible at the moment; 2) very prominent sleepiness, which occurs acutely together with fatigue and is always combined with it; 3) unusual clear but somewhat estranged perception of the environment: the patient sees and understands everything and is oriented well enough, but cannot take a clear and adequate action, 4) full recovery of the impaired functions after the drug is discontinued; 5) AGS recurrence after the drug is taken again.	glaucine	134-142	jagged canonical Notch ligand 1	Homo sapiens	27-30
17243616-3	2006	The hallucination-like effect of glaucine, described earlier by the author of this article, which is manifested by bright and colorful visual images, may be considered a facultative AGS component.	glaucine	33-41	jagged canonical Notch ligand 1	Homo sapiens	182-185
10844113-4	2000	Pretreatment with glaucine (10 mg ml(-1), 10 min inhalation, 30 min pre- and 3 h post-antigen exposure) markedly reduced airway hyperreactivity to histamine, eosinophil lung accumulation, and increased eosinophil peroxidase activity in bronchoalveolar lavage fluid 24 h after exposure of conscious guinea pigs to aerosol antigen.	glaucine	18-26	eosinophil peroxidase	Cavia porcellus	202-223
10455321-3	1999	We examined the effects of the alkaloid S-(+)-glaucine, a PDE4 inhibitor, on human isolated bronchus and granulocyte function.	glaucine	40-54	phosphodiesterase 4A	Homo sapiens	58-62
10455321-5	1999	Glaucine selectively inhibited PDE4 from human bronchus and polymorphonuclear leukocytes (PMN) in a non-competitive manner (Ki=3.4 microM).	glaucine	0-8	phosphodiesterase 4A	Homo sapiens	31-35
10455321-13	1999	Glaucine augmented cyclic AMP levels in human polymorphonuclear leukocytes challenged with N-formyl-Met-Leu-Phe (FMLP) or isoprenaline, and inhibited FMLP-induced superoxide generation, elastase release, leukotriene B4 production, [Ca2+]i signal and platelet aggregation as well as opsonized zymosan-, phorbol myristate acetate-, and A23187-induced superoxide release.	glaucine	0-8	formyl peptide receptor 1	Homo sapiens	91-111
10455321-13	1999	Glaucine augmented cyclic AMP levels in human polymorphonuclear leukocytes challenged with N-formyl-Met-Leu-Phe (FMLP) or isoprenaline, and inhibited FMLP-induced superoxide generation, elastase release, leukotriene B4 production, [Ca2+]i signal and platelet aggregation as well as opsonized zymosan-, phorbol myristate acetate-, and A23187-induced superoxide release.	glaucine	0-8	formyl peptide receptor 1	Homo sapiens	113-117
10455321-13	1999	Glaucine augmented cyclic AMP levels in human polymorphonuclear leukocytes challenged with N-formyl-Met-Leu-Phe (FMLP) or isoprenaline, and inhibited FMLP-induced superoxide generation, elastase release, leukotriene B4 production, [Ca2+]i signal and platelet aggregation as well as opsonized zymosan-, phorbol myristate acetate-, and A23187-induced superoxide release.	glaucine	0-8	formyl peptide receptor 1	Homo sapiens	150-154
10455321-14	1999	The inhibitory effect of glaucine on superoxide generation by FMLP was reduced by H-89.	glaucine	25-33	formyl peptide receptor 1	Homo sapiens	62-66
10455321-17	1999	The very low PDE4/binding site ratio found for glaucine makes this compound attractive for further structure-activity studies.	glaucine	47-55	phosphodiesterase 4A	Homo sapiens	13-17
7503766-0	1995	The inhibitory effects of boldine, glaucine, and probucol on TPA-induced down regulation of gap junction function.	glaucine	35-43	plasminogen activator, tissue type	Rattus norvegicus	61-64
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	plasminogen activator, tissue type	Rattus norvegicus	76-79
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	plasminogen activator, tissue type	Rattus norvegicus	201-204
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	gap junction protein, alpha 1	Rattus norvegicus	252-263
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	gap junction protein, alpha 1	Rattus norvegicus	265-269
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	plasminogen activator, tissue type	Rattus norvegicus	201-204
7503766-5	1995	Additionally, boldine, glaucine, and probucol, each at 50 microM, inhibited TPA-induced translocation of protein kinase C (PKC) to the particulate fraction of the cells, with concomitant inhibition of TPA-induced hyperphosphorylation of gap junctional connexin 43 (cx43) and TPA-induced internalisation of cx43 protein from the plasma membrane of the cells.	glaucine	23-31	gap junction protein, alpha 1	Rattus norvegicus	306-310
7596952-4	1995	The non-phenolic glaucine inhibited the 2,2"-azobis-(2-amidinopropane)(AAP)-induced inactivation of lysozyme with an IC50 value of 12 microM, while the corresponding values for the phenolic coclaurine and norarmepavine were 10 and 20 microM, respectively.	glaucine	17-25	serpin family F member 2	Homo sapiens	71-74
8319926-2	1993	Laudanosoline, protopapaverine, anonaine, apomorphine, glaucine, boldine, bulbocapnine, tetrahydroberberine and stepholidine produced a dose-dependent inhibition of microsomal lipid peroxidation induced by Fe2+/ascorbate, CCl4/NADPH or by Fe3+ ADP/NADPH.	glaucine	55-63	C-C motif chemokine ligand 4	Homo sapiens	222-226
1819921-5	1991	Applied duodenally, the dehydrogenated glaucine derivatives also manifested a gradually occurring hypotensive effect, whereby DG4 again caused the most pronounced blood pressure drop.	glaucine	39-47	desmoglein 3	Homo sapiens	126-129